Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia
Description
Brief Summary
Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb
loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a
major cause of death and disability (secondary to myocardial infarction, stroke and
amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years
respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin
and clopidogrel (previously referred to as "resistance") is associated with an increased
risk of recurrent cardiovascular events after percutaneous coronary interventions and acute
coronary syndromes. The prevalence and significance of HPR in patients with critical limb
ischemia treated with aspirin and/or clopidogrel is not known.
The investigators project aims to investigate the prevalence of HPR (to aspirin and
clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at
University of Southern California affiliated hospitals (Los Angeles County Hospital and Keck
Hospital of USC).
Phase
N/AInclusion and Exclusion Criteria
- EXPERIMENTAL GROUP: Patients with a diagnosis of CLI and uninterrupted treatment with aspirin and/or clopidogrel for at least one week before testing.
- CONTROL GROUP: 10 normal volunteers without any known co-morbidities
- Chronic use of nonsteroidal anti-inflammatory drugs, thrombocytopenia (platelet count <100 × 103/
Sites
Please contact Melissa Minor to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI